Longer Infusion Gives Bivalirudin the Upper Hand in PCI
(MedPage Today) -- Acute stent thrombosis, major bleeding rates favorable in meta-analysis
AbstractCerebral amyloid angiopathy-related inflammation is a syndrome of reversible encephalopathy with cerebral amyloid angiopathy, however the pathology is not well understood. We clear a part of the pathology through the first case of an 80-year-old man with cerebral amyloid angiopathy-related inflammation induced by relapsing polychondritis (RP) analysis. An 80-year-old man was diagnosed with RP by auricular cartilage biopsy. Almost no abnormality including intracranial microbleeding was detected by cranial magnetic resonance image (MRI) at diagnosis. However, he developed a headache and hallucination after five month...
Authors: Li T, Yuan D, Yuan J Abstract Thrombosis, the localized clotting of blood that affects arterial or venous circulation, is one of the leading causes of death worldwide. Arterial thrombosis is commonly initiated by vascular endothelial injury, while venous thrombosis mainly stems from blood stasis. Despite these differences, platelet adhesion, activation and aggregation, and fibrin formation as a result of coagulation constitute the fundamental processes of thrombus formation. Antithrombotic drugs permitted on the clinical currently can dramatically reduce major adverse cardiovascular events; however, they c...
assicotte M, Smith WT, Berkowitz SD, Schmidt S, Price V, Prins MH, Kubitza D, EINSTEIN-Jr. Phase 3 Investigators Abstract BACKGROUND: Recently, the randomized EINSTEIN-Jr. study showed similar efficacy and safety for rivaroxaban and standard anticoagulation for treatment of pediatric venous thromboembolism (VTE). The rivaroxaban dosing strategy was established based on phase 1 and 2 data in children and through pharmacokinetic (PK) modeling. METHODS: Rivaroxaban treatment with tablets or the newly-developed granules-for-oral suspension formulation was bodyweight-adjusted and administered once-daily, twice-dai...
AbstractAtrial fibrillation (AF) patients with mid-range left ventricular ejection fraction (mrEF) of 40 –49% have neither preserved (pEF > 50%) nor reduced (rEF
Bleeding due to inherited defects in fibrinolytic cascade genes is rare. Fibrinolysis is an in-built regulatory mechanism responsible for plasmin-mediated dissolution of fibrin clots due to interplay between activators and inhibitors of fibrinolysis. Thus, deficiency of the inhibitors of fibrinolysis, either alpha-2 antiplasmin ( α2-AP) or plasminogen activator inhibitor- 1 (PAI-1) results in hyperfibrinolysis leading to premature fibrin clot lysis and associated hemorrhagic diathesis. Prevalence of congenital disorders of fibrinolysis is unknown.
We describe a 43-year-old woman presenting with an asymptomatic LRVT complicating NCS. She was referred to our hospital for investigation of dysfunctional uterine bleeding, and detailed examination revealed endometrial cancer. Computed tomography angiography (CTA) and Doppler ultrasonography revealed compression of the LRV between the aorta and the SMA, as well as an LRVT. CTA performed 4 months after the administration of an anticoagulant showed complete disappearance of the LRVT. We have also included a review of published reports describing LRVT complicating NCS and discussed the clinical features of such a presentation.
LVAD thrombolysis can be effective but carries a bleeding risk. Existing data suggest intraventricular (vs peripheral) delivery may reduce bleeding, but is associated with early recurrence. We have developed a novel hybrid thrombolytic approach (hTL) using an initial high dose LV delivery of alteplase followed by a maintenance LV infusion.
Chronic heart failure (CHF) is one of the most severe and adverse diseases of the cardiovascular system, which requires heart transplantation (HT) for patient. Implantation of the left ventricular assist device (LVAD) is the treatment option instead of HT. LVAD can be implanted as a bridge to transplantation and destination therapy (DT). Unfortunately, DT of the LVAD has side effects such as bleeding and thrombosis. These side effects occur because of the non-physiological high shear stress of the LVAD, which causes platelet degradation.
Continuous-flow left ventricular assist devices (CFLVAD) in management of end-stage heart failure continues to expand. Adverse events however remain high. Better understanding of platelet activation in the context of CFLVAD therapy may help reduce bleeding and pump thrombosis (PT) risks to patients.
Bleeding complications during left ventricular assist device (LVAD) support pose anticoagulation challenges as risk of discontinuation of anticoagulation, even in the setting of bleeding, may pose an increased risk of subsequent LVAD hemolysis or thrombosis. We assessed whether discontinuation of anticoagulation in HM3 patients whose bleeding concerns preventing anticoagulation would adversely impact outcomes.